FDA authorises Jazz Pharma’s sleep disorder therapy Sunosi
March 22, 2019Medical Communications, Sales and Marketing FDA, jazz pharmaceuticals, pharma, sleep apnoea
Jazz Pharmaceuticals has announced that its dopamine and norepinephrine reuptake inhibitor (DNRI) Sunosi (solriamfetol) has been approved by the FDA …
Top Ten most popular articles on Pharmafile.com this week!
March 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz
This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …
Specialists petition FDA over opioid approval process
March 22, 2019Medical Communications FDA, approval process, opioid crisis, opioids, painkillers
FDA officials have called on the federal agency to halt the approval of new narcotic painkillers. Dr Sidney Wolfe, a …
Tate art galleries will not accept donations from Sacklers
March 22, 2019Medical Communications OxyContin, Purdue Pharma, Sacklers, Tate, art galleries, opioid crisis
The Tate network of art galleries has said it will no longer accept gifts from the notorious Sackler family, the …
Department of Veteran Affairs to offer Janssen’s esketamine to veterans with depression
March 21, 2019Medical Communications Jannsen, Spravato, VA, depression, esketamine, military, veteran affairs
The United States Department of Veteran Affairs (VA), the federal agency responsible for providing healthcare services to military veterans, is …
Breathing life into COPD research
March 21, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COPD, GSK, feature
Alison Hollands, Vice President, Respiratory, UK Pharmaceuticals at GlaxoSmithKline, addresses the importance of implementing the latest approaches to treating COPD …
Biogen and Eisai discontinue Phase 3 Alzheimer’s trial
March 21, 2019Research and Development Alzheimer's, Biogen, CNS, Eisai, mental health
Biogen and Eisai have announced their decision to discontinue a Phase 3 trial looking into the efficacy and safety of …
Celgene inks drug discovery deal worth at least £25m with AI firm Exscientia
March 21, 2019Research and Development Celgene, Exscientia, drug discovery, pharma
Celgene has entered into a new three-year partnership with British artificial intelligence and drug discovery firm Exscientia to the value …
J&J bows to PETA pressure and drops forced swim tests in mice
March 21, 2019Medical Communications J&J, JJ, Johnson & Johnson, PETA, animal welfare, pharma
Johnson & Johnson has announced it is to end its practice of forced swim tests on mice, rats and other …
Antiepileptics increase the risk of pneumonia in people with Alzheimer’s disease
March 21, 2019Research and Development Alzheimer's, R&D, adverse events, antiepileptic drugs, epilepsy, pneumonia
Antiepileptic drugs increase the risk of pneumonia in people living with Alzheimer’s disease, according to research from the University of …
Venezuela relaunch pharmaceutical industry with Chinese and Russian backing
March 21, 2019Manufacturing and Production China, Maduro, Russia, USA, Venezuela, pharma
President Maduro has pledged to relaunch Venezuela’s pharmaceutical industry, as part of an effort to address shortages of medicines in …
Roche’s Tecentriq chalks up another FDA approval, this time in first-line extensive-stage small cell lung cancer
March 20, 2019Research and Development, Sales and Marketing FDA, Roche, lung cancer, pharma, tecentriq
Roche has secured another US approval for its immunotherapy Tecentriq (atezolizumab), as the FDA reveals its approval of the drug …
FDA puts multiple myeloma trial on hold after patient deaths
March 20, 2019Research and Development AbbVie, FDA, Roche, clinical trials, multiple myeloma
The FDA has placed a partial clinical hold on studies of multiple myeloma treatment Venclexta/Venclyxto (venetoclax) following a number of …
FDA approves first-ever postpartum depression therapy: Sage Therapeutics’ Zulresso
March 20, 2019Research and Development, Sales and Marketing FDA, Sage Therapeutics, depression, pharma, postpartum depression
The FDA has announced its decision to approve Sage Therapeutics’ intraveneous injection Zulresso (brexanolone), marking the first authorisation of a …
Pfizer and Merck discontinue Phase 3 avelumab ovarian cancer trial
March 20, 2019Research and Development Merck KGaA, Pfizer, javelin, oncology, ovarian cancer
Pfizer and Merck KGaA have chosen to discontinue the Phase 3 JAVELIN trial looking into avelumab in combination with chemotherapy …
Dame Sally Davies says medicinal cannabis legalisation has opened Pandora’s Box
March 20, 2019Research and Development
England’s Chief Medical Officer (CMO), Dame Sally Davies has said the legalisation of medicinal cannabis has “opened a Pandora’s Box,” …
Breast cancer mortality rates fall faster in Britain than elsewhere in Europe
March 19, 2019Manufacturing and Production, Research and Development Cancer, EU, Europe, France, Italy, Poland, UK, breast cancer, german, oncology
Death rates from breast cancer are falling faster in Britain than in any of the other six most populous countries …
AZ’s Farxiga reduces major adverse cardiovascular event risk in type 2 diabetes, new data shows
March 19, 2019Manufacturing and Production, Research and Development AstraZeneca, cardiovascular, farxiga, pharma
AstraZeneca has lifted the curtain on new Phase 3 data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), reinforcing …
Shortage of cancer doctors puts NHS patients at risk
March 19, 2019Manufacturing and Production, Research and Development Cancer, NHS, oncologists, radiology, shortfall, staff
A shortage of cancer doctors is putting patients at risk, according to a new report from the Royal College of …
FDA approves first paediatric treatment for intra-abdominal and urinary tract infections in over 10 years
March 19, 2019Manufacturing and Production, Sales and Marketing Allergan, Avycaz, FDA, pharma
Allergan has revealed that Avycaz (ceftazidime and avibactam) has been awarded an expansion of its label by the FDA to include …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
